Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
Other Sizes |
|
ACBI1 (ACBI-1) is PROTAC degrader of BAF ATPase subunits SMARCA2 and SMARCA4 (DC50 = 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells) with anticancer activity.It is composed of a bromodomain ligand, a linker, and the E3 ubiquitin ligase VHL. ACBI1 has anti-proliferative effects and can induceapoptosis. Italso degrades the polybromo-associated BAF (PBAF) complex member PBRM1.
ln Vitro |
ACBI1 exhibits anti-proliferative action at 1–10,000 nM over 3–7 days [1]. SK-MEL-5 cells undergo apoptosis when exposed to ACBI1 (0.3 µM; 100 hours) [1]. The E3 ubiquitin ligase von Hippel-Lindau, a linker, and a bromodomain ligand make up ACBI1[1].
|
---|---|
Cell Assay |
Cell proliferation assay[1]
Cell Types: MV-4-11, NCI-H1568 Cell Tested Concentrations: 0-1000 nM Incubation Duration: 3-7 days Experimental Results: demonstrated anti-proliferative activity, IC50 of MV-4 is 29, 68 nM -11, NCI-H1568 cells. Apoptosis analysis[1] Cell Types: SK-MEL-5 Cell Tested Concentrations: 0.3 µM Incubation Duration: 100 hrs (hours) Experimental Results: Induction of apoptosis in SK-MEL-5 cells. |
References |
[1]. Farnaby W, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019 Jul;15(7):672-680.
|
Molecular Formula |
C49H58FN9O7S
|
---|---|
Molecular Weight |
936.1043
|
CAS # |
2375564-55-7
|
SMILES |
S1C([H])=NC(C([H])([H])[H])=C1C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])C([H])([H])OC1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N1C([H])([H])C([H])([H])N(C2C(N([H])[H])=NN=C(C3=C([H])C([H])=C([H])C([H])=C3O[H])C=2[H])C([H])([H])C1([H])[H])C([H])([H])N([H])C([C@]1([H])C([H])([H])[C@]([H])(C([H])([H])N1C([C@]([H])(C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])N([H])C(C1(C([H])([H])C1([H])[H])F)=O)=O)O[H])=O
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~106.83 mM)
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.0683 mL | 5.3413 mL | 10.6826 mL | |
5 mM | 0.2137 mL | 1.0683 mL | 2.1365 mL | |
10 mM | 0.1068 mL | 0.5341 mL | 1.0683 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.